Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROSPER: Efficacy and Safety Study of Enzalutamide in Nonmetastatic Castration-Resistant Prostate Cancer
KCT0001047Phase 3Recruiting
- Sponsor
- Medivation
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of enzalutamide in prostate cancer (PCa), sponsored by Medivation. Started Mar 2014; status: recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on KCT0001047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0001047.